Merck & Co. (MRK)
(Delayed Data from NYSE)
$130.72 USD
+3.72 (2.93%)
Updated Apr 25, 2024 04:02 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
MRK 130.72 +3.72(2.93%)
Will MRK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRK
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Other News for MRK
Merck price target raised by $5 at Wells Fargo, here's why
Merck & Company: A Strong Buy on Robust Performance and Future Growth Prospects
Merck & Co. Outperforms with Strong Keytruda Sales and Raised Guidance: A Buy Rating Affirmed
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Globus Medical (GMED) and Merck & Company (MRK)
Merck & Company (MRK) Gets a Buy from Barclays